Moderna Current Ratio 2017-2021 | MRNA

Current and historical current ratio for Moderna (MRNA) from 2017 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Moderna current ratio for the three months ending June 30, 2021 was 1.24.
Moderna Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $10.97B $8.84B 1.24
2021-03-31 $11.70B $8.44B 1.39
2020-12-31 $6.30B $4.39B 1.44
2020-09-30 $3.58B $1.47B 2.43
2020-06-30 $2.80B $0.16B 17.30
2020-03-31 $1.25B $0.14B 9.29
2019-12-31 $1.13B $0.14B 7.89
2019-09-30 $1.09B $0.15B 7.40
2019-06-30 $1.10B $0.16B 6.78
2019-03-31 $1.14B $0.16B 7.17
2018-12-31 $1.56B $0.22B 7.02
2018-09-30 $0.00B 0.00
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $0.78B $0.19B 4.09
2016-12-31 $1.09B $0.16B 6.68
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $131.807B $0.803B
Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA- 2752 for Relapsed/Refractory solid tumors malignancies. Moderna Inc. is based in Cambridge, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76